JP7083497B2 - がんの処置のための併用療法 - Google Patents

がんの処置のための併用療法 Download PDF

Info

Publication number
JP7083497B2
JP7083497B2 JP2018505454A JP2018505454A JP7083497B2 JP 7083497 B2 JP7083497 B2 JP 7083497B2 JP 2018505454 A JP2018505454 A JP 2018505454A JP 2018505454 A JP2018505454 A JP 2018505454A JP 7083497 B2 JP7083497 B2 JP 7083497B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
composition
azacitidine
acceptable salt
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018505454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522038A5 (enExample
JP2018522038A (ja
Inventor
デイビッド ジェイ． ベアス，
スティーブン エル． ワーナー，
アダム シディクイ－ジェイン，
クリフォード ジェイ． ワットコット，
ウォンタク キム，
Original Assignee
スミトモ ファーマ オンコロジー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スミトモ ファーマ オンコロジー， インコーポレイテッド filed Critical スミトモ ファーマ オンコロジー， インコーポレイテッド
Publication of JP2018522038A publication Critical patent/JP2018522038A/ja
Publication of JP2018522038A5 publication Critical patent/JP2018522038A5/ja
Application granted granted Critical
Publication of JP7083497B2 publication Critical patent/JP7083497B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018505454A 2015-08-03 2016-08-03 がんの処置のための併用療法 Expired - Fee Related JP7083497B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562200499P 2015-08-03 2015-08-03
US62/200,499 2015-08-03
PCT/US2016/045423 WO2017024073A1 (en) 2015-08-03 2016-08-03 Combination therapies for treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021004166A Division JP2021054868A (ja) 2015-08-03 2021-01-14 がんの処置のための併用療法

Publications (3)

Publication Number Publication Date
JP2018522038A JP2018522038A (ja) 2018-08-09
JP2018522038A5 JP2018522038A5 (enExample) 2019-09-12
JP7083497B2 true JP7083497B2 (ja) 2022-06-13

Family

ID=57943631

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018505454A Expired - Fee Related JP7083497B2 (ja) 2015-08-03 2016-08-03 がんの処置のための併用療法
JP2021004166A Pending JP2021054868A (ja) 2015-08-03 2021-01-14 がんの処置のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021004166A Pending JP2021054868A (ja) 2015-08-03 2021-01-14 がんの処置のための併用療法

Country Status (12)

Country Link
US (4) US10568887B2 (enExample)
EP (1) EP3331510A4 (enExample)
JP (2) JP7083497B2 (enExample)
KR (1) KR20180034538A (enExample)
CN (1) CN108289861B (enExample)
AU (1) AU2016301315C1 (enExample)
BR (1) BR112018002427A8 (enExample)
CA (1) CA2993659A1 (enExample)
IL (1) IL257073A (enExample)
MX (1) MX2018001289A (enExample)
RU (1) RU2759963C2 (enExample)
WO (1) WO2017024073A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
AU2016301315C1 (en) * 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
WO2020077300A1 (en) * 2018-10-12 2020-04-16 Tolero Pharmaceuticals, Inc. Methods for monitoring tumor lysis syndrome
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
WO2020150326A1 (en) * 2019-01-15 2020-07-23 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
JP2022525149A (ja) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置
CN113230385A (zh) * 2021-05-08 2021-08-10 深圳市保尔医疗服务有限公司 一种缓解癌痛和缓解癌症的药物配方及使用方法
WO2024239512A1 (zh) * 2023-05-22 2024-11-28 劲方医药科技(上海)有限公司 药物组合及其在治疗癌症中的用途

Family Cites Families (198)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2338043A1 (fr) 1976-01-13 1977-08-12 Delmar Chem Derives de 4-arylpiperidine et procedes de production
US4132710A (en) 1976-12-20 1979-01-02 Ayerst, Mckenna And Harrison, Ltd. [2]Benzopyrano[3,4-c]pyridines and process therefor
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IN164232B (enExample) 1986-04-11 1989-02-04 Hoechst India
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JP2691986B2 (ja) 1987-08-28 1997-12-17 チッソ株式会社 ピリジン骨格を有する光学活性化合物の製造法
DE3743824C2 (de) 1987-12-23 1997-03-06 Hoechst Ag Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2069040T3 (es) 1990-08-09 1995-05-01 Francaise Coop Pharma Solucion estable de hipoclorito de sodio.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JPH0641075A (ja) 1990-09-01 1994-02-15 Kazuo Achinami 新規な１，４−ジヒドロピリジン化合物及びその製造方法
JPH05192145A (ja) 1991-04-02 1993-08-03 Hoechst Ag 固定化生体触媒、その製造およびカラムリアクター中でのエステル合成におけるその使用
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9422836D0 (en) 1994-11-11 1995-01-04 Wainscoat James Monitoring malignant disease
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (en) 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
AU705563B2 (en) 1995-07-28 1999-05-27 Marie Curie Cancer Care Transport proteins and their uses
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US5733920A (en) 1995-10-31 1998-03-31 Mitotix, Inc. Inhibitors of cyclin dependent kinases
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DK0780386T3 (da) 1995-12-20 2003-02-03 Hoffmann La Roche Matrixmetalloproteaseinhibitorer
EP0888458A4 (en) 1996-02-20 2004-05-06 Sloan Kettering Institutefor C COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
US6087366A (en) 1996-03-07 2000-07-11 The Trustees Of Columbia University In The City Of New York Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
US5849733A (en) 1996-05-10 1998-12-15 Bristol-Myers Squibb Co. 2-thio or 2-oxo flavopiridol analogs
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EP0922030A1 (en) 1996-08-23 1999-06-16 Pfizer Inc. Arylsulfonylamino hydroxamic acid derivatives
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
HUP0000852A2 (hu) 1997-02-03 2001-05-28 Pfizer Products Inc. Aril-szulfonil-amino-hidroxámsav-származékok, valamint e vegyületeket tartalmazó gyógyászati készítmények
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
JP2000507975A (ja) 1997-02-07 2000-06-27 ファイザー・インク Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
NZ336836A (en) 1997-02-11 2001-02-23 Pfizer Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
GB9704444D0 (en) 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
TR200000368T2 (tr) 1997-08-08 2000-07-21 Pfizer Products Inc. Ariloksiariarilsülfonilamino hidroksamik asit türevleri.
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US7064193B1 (en) 1997-09-17 2006-06-20 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
AU744939B2 (en) 1997-09-26 2002-03-07 Merck & Co., Inc. Novel angiogenesis inhibitors
WO1999016787A1 (en) 1997-09-26 1999-04-08 Washington University Cell death agonists
SK6652000A3 (en) 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
DE19802449A1 (de) 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
US6437136B2 (en) 1998-01-23 2002-08-20 Aventis Pharma Deutschland Gmbh Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
DE19809649A1 (de) 1998-03-06 1999-09-09 Hoechst Marion Roussel De Gmbh Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
FR2780056B1 (fr) 1998-06-18 2000-08-04 Hoechst Marion Roussel Inc Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre
DE69923322T2 (de) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
US6268499B1 (en) 1998-08-10 2001-07-31 Hoffman-La Roche Inc. Process and intermediates for preparation of substituted piperidine-epoxides
AU1029500A (en) 1998-08-29 2000-03-21 Miklos Ghyczy Pharmaceutical and/or diet product
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
EP1210098A1 (en) 1999-04-07 2002-06-05 Thomas Jefferson University Enhancement of peptide cellular uptake
US6511993B1 (en) 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
WO2001012661A2 (en) 1999-08-16 2001-02-22 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, The National Institutes Of Health RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS
US6821990B2 (en) 2000-01-18 2004-11-23 Aventis Pharma Deutschland Gmbh Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
US6576647B2 (en) 2000-01-18 2003-06-10 Aventis Pharmaceuticals Inc. Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AU2001253618A1 (en) 2000-04-21 2001-11-07 Arch Development Corporation Flavopiridol drug combinations and methods with reduced side effects
WO2002020568A2 (en) 2000-09-06 2002-03-14 Abbott Laboratories Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
AU2002228849A1 (en) * 2000-12-08 2002-06-18 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors
WO2002069995A2 (en) 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
AU2002305099A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty alcohol drug conjugates
AU2002303164A1 (en) 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
KR20030026069A (ko) 2001-09-24 2003-03-31 주식회사 엘지생명과학 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물
EP1436406A4 (en) 2001-09-24 2004-10-13 Blood Ct Res Foundation METHOD FOR MODULATING OR EXAMINING THE KU70 MIRROR IN CELLS
WO2003040168A2 (en) 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
WO2003057158A2 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
CA2478047C (en) 2002-03-01 2014-01-21 Immunomedics, Inc. Rs7 antibodies
US20040106647A1 (en) 2002-06-28 2004-06-03 Schneider Michael D. Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
CA2496400A1 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
EP1620109A2 (en) 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
GB0315259D0 (en) 2003-06-30 2003-08-06 Cyclacel Ltd Use
EA015363B1 (ru) 2003-07-18 2011-06-30 Эмджен Инк. Агенты, специфически связывающие фактор роста гепатоцитов, и их применение
CN1302004C (zh) 2003-08-22 2007-02-28 浙江海正药业股份有限公司 一种阿糖胞苷的制备方法
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
WO2006101846A1 (en) 2005-03-16 2006-09-28 Aventis Pharmaceuticals Inc. Dosing regimen of flavopiridol for treating cancer in particular cll
WO2006099667A1 (en) 2005-03-21 2006-09-28 The Walter And Eliza Hall Institute Of Medical Research Prophylactic and therapeutic agents and uses therefor
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US8221966B2 (en) 2006-03-31 2012-07-17 Dana Farber Cancer Institute Methods of determining cellular chemosensitivity
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
US9360473B2 (en) 2006-08-16 2016-06-07 Eutropics Pharmaceuticals, Inc. Assay system to identify therapeutic agents
RU2474582C2 (ru) * 2006-10-19 2013-02-10 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы
MX2009009117A (es) 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
GB0706633D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd Combination
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
CA2687204C (en) 2007-05-15 2015-11-24 Piramal Life Sciences Limited A synergistic pharmaceutical combination for the treatment of cancer
WO2009014642A1 (en) 2007-07-19 2009-01-29 Amgen Inc. Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
CA2708264C (en) 2007-12-10 2018-07-03 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
TWI378781B (en) 2008-03-12 2012-12-11 Jung Tang Huang A belt integrated with stress sensing and output reaction
WO2009137664A1 (en) 2008-05-07 2009-11-12 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of bcl-2 family and uses thereof
PL2307002T3 (pl) * 2008-06-09 2013-05-31 Cyclacel Ltd Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
CA2751293A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
WO2010147961A1 (en) 2009-06-15 2010-12-23 Precision Therapeutics, Inc. Methods and markers for predicting responses to chemotherapy
WO2011088137A2 (en) 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
US8372819B2 (en) 2010-04-11 2013-02-12 Salk Institute For Biological Studies Methods and compositions for targeting skip
CN103154246B (zh) 2010-05-14 2015-11-25 达那-法伯癌症研究所 用于治疗白血病的组合物和方法
SG180031A1 (en) * 2010-10-15 2012-05-30 Agency Science Tech & Res Combination treatment of cancer
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
WO2012122370A2 (en) 2011-03-08 2012-09-13 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN103608012A (zh) 2011-06-14 2014-02-26 诺华股份有限公司 在癌症如骨髓增殖性肿瘤治疗中的帕比司他与鲁索利替尼的组合
EP2561867A1 (en) 2011-08-22 2013-02-27 Lead Discovery Center GmbH CDK9 inhibitors in the treatment of midline carcinoma
US9012215B2 (en) 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
US20130122492A1 (en) 2011-11-14 2013-05-16 Kellbenx Inc. Detection, isolation and analysis of rare cells in biological fluids
WO2013082660A1 (en) 2011-12-09 2013-06-13 Alfred Health Prediction method
WO2013138702A2 (en) 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
AU2013235425B2 (en) 2012-03-20 2017-09-21 Dana Farber Cancer Institute, Inc. Inhibition of MCL-1 and/or BFL-1/A1
WO2013170176A2 (en) 2012-05-10 2013-11-14 Eutropics Pharmaceuticals, Inc. Surrogate functional diagnostics test for cancer
WO2013182519A1 (en) 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
WO2013188355A1 (en) 2012-06-12 2013-12-19 Merck Sharp & Dohme Corp. Cdk inhibitor for treating refractory chronic lymphocytic leukemia
EP2863920B1 (en) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Quinoline derivatives for use in the tratment of breast cancer
WO2013188978A1 (en) 2012-06-20 2013-12-27 Cytospan Technologies Corporation Apparatus and method for quantification of replicative lifespan and observation of senescene
WO2014047342A1 (en) 2012-09-19 2014-03-27 Dana-Farber Cancer Institute, Inc. Dynamic bh3 profiling
US9241941B2 (en) 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes
HK1212683A1 (zh) 2012-09-26 2016-06-17 Mannkind Corporation 多个激酶途径抑制剂
SG11201502757QA (en) 2012-10-09 2015-05-28 Igenica Biotherapeutics Inc Anti-c16orf54 antibodies and methods of use thereof
WO2014065275A1 (ja) 2012-10-23 2014-05-01 国立大学法人福井大学 腫瘍融解症候群の治療薬及び予防薬
EP2912178B1 (en) 2012-10-25 2020-06-17 Whitehead Institute For Biomedical Research Super-enhancers and methods of use thereof
EP2945628B1 (en) 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
US10732182B2 (en) 2013-08-01 2020-08-04 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014323526B2 (en) 2013-09-19 2020-07-23 Dana-Farber Cancer Institute, Inc. Methods of BH3 profiling
CA2920192A1 (en) 2013-09-27 2015-04-02 Immunomedics, Inc. Anti-trop-2 antibody-drug conjugates and uses thereof
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
US11446309B2 (en) 2013-11-08 2022-09-20 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors
US9925192B2 (en) 2014-02-28 2018-03-27 Merck Sharp & Dohme Corp. Method for treating cancer
WO2015161247A1 (en) * 2014-04-17 2015-10-22 Igenica Biotherapeutics, Inc. Humanized anti-c16orf54 antibodies and methods of use thereof
US10577417B2 (en) 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10300073B2 (en) 2014-10-14 2019-05-28 The Regents Of The University Of California Use of CDK9 and BRD4 inhibitors to inhibit inflammation
MX385762B (es) 2014-11-07 2025-03-18 Sumitomo Pharma Oncology Inc Métodos para el control transcripcional objetivo en regiones del super mejorador.
WO2016115105A1 (en) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
EP3270945A4 (en) 2015-03-18 2018-09-05 Massachusetts Institute of Technology Selective mcl-1 binding peptides
WO2016154380A1 (en) 2015-03-24 2016-09-29 Eutropics Pharmaceuticals, Inc. Surrogate functional biomarker for solid tumor cancer
WO2016161248A1 (en) 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
AU2016252609B2 (en) 2015-04-20 2022-06-30 Sumitomo Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
AU2016255749B2 (en) 2015-04-27 2021-10-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for assessing toxicity using Dynamic BH3 profiling
HUE045585T2 (hu) 2015-05-18 2020-01-28 Tolero Pharmaceuticals Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok
AU2016301315C1 (en) * 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
WO2017075349A2 (en) 2015-10-30 2017-05-04 Massachusetts Institute Of Technology Selective mcl-1 binding peptides
US9782232B1 (en) 2016-04-25 2017-10-10 Novartis Ag Automated intraocular pressure tamponade
CN105919955A (zh) 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种鲁索利替尼制剂及其应用
EP3484455A2 (en) 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
CA3047557A1 (en) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
US20190314357A1 (en) 2018-04-13 2019-10-17 Tolero Pharmaceuticals, Inc. Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer
WO2019246421A1 (en) 2018-06-21 2019-12-26 Tolero Pharmaceuticals, Inc. Deuterated alvocidib and alvocidib prodrugs

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Blood, 2018, 132, (Supplement 1), p.4355
Haematologica, 2012, 97(11), pp.1736-1742
haematologica, 2013, 98 (s1), p.19, Abstract No. P047
PLoS ONE, 2010, Vol.5, Issue 2, e9001, pp.1-10

Also Published As

Publication number Publication date
BR112018002427A8 (pt) 2022-10-18
US20200215071A1 (en) 2020-07-09
US20210228582A1 (en) 2021-07-29
EP3331510A1 (en) 2018-06-13
CN108289861A (zh) 2018-07-17
US10568887B2 (en) 2020-02-25
KR20180034538A (ko) 2018-04-04
WO2017024073A1 (en) 2017-02-09
US10682356B2 (en) 2020-06-16
US20180256580A1 (en) 2018-09-13
AU2016301315A1 (en) 2018-02-22
AU2016301315C1 (en) 2022-07-07
AU2016301315B2 (en) 2021-12-23
RU2018106886A (ru) 2019-09-05
AU2016301315A8 (en) 2018-03-15
JP2018522038A (ja) 2018-08-09
CN108289861B (zh) 2021-11-02
IL257073A (en) 2018-03-29
US20200054642A1 (en) 2020-02-20
HK1254882A1 (zh) 2019-07-26
MX2018001289A (es) 2018-04-30
BR112018002427A2 (pt) 2018-09-18
JP2021054868A (ja) 2021-04-08
CA2993659A1 (en) 2017-02-09
RU2759963C2 (ru) 2021-11-19
EP3331510A4 (en) 2019-04-03
RU2018106886A3 (enExample) 2019-12-31
US10835537B2 (en) 2020-11-17

Similar Documents

Publication Publication Date Title
JP2021054868A (ja) がんの処置のための併用療法
US11026900B2 (en) Treatment or prevention of cardiovascular events via the administration of a colchicine derivative
JP2021512105A (ja) 消化管間質腫瘍の治療のための併用療法
Diwan et al. Glibenclamide improves kidney and heart structure and function in the adenine-diet model of chronic kidney disease
BR112020005039A2 (pt) combinação de um inibidor de btk e um inibidor de cdk9 para tratar câncer
US20160129003A1 (en) Pharmaceutical Combinations
KR20200036879A (ko) 3세대 egfr 타이로신 키나아제 억제제 및 사이클린 d 키나아제 억제제의 치료적 조합물
Lee et al. Suppression of inflammation response by a novel A3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling
CA3013342A1 (en) Combinations to treat cancer
CA3005961C (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
Couvreur et al. The Ceiling Effect of Pharmacological Postconditioning with the Phytoestrogen Genistein Is Reversed by the GSK3β Inhibitor SB 216763 [3-(2, 4-Dichlorophenyl)-4 (1-methyl-1H-indol-3-yl)-1H-pyrrole-2, 5-dione] through Mitochondrial ATP-Dependent Potassium Channel Opening
CN106999525A (zh) 用于治疗间皮瘤的菜蓟滴定提取物
HK1254882B (en) Combination therapies for treatment of cancer
US11052101B2 (en) Methods for treating cancer using purine analogs by depleting intracellular ATP
WO2016012982A1 (en) Combination therapy for the treatment of resistant breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190805

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200715

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20201002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220525

R150 Certificate of patent or registration of utility model

Ref document number: 7083497

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees